WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
ImmunoScape | August 13, 2020
ImmunoScape (www.ImmunoScape.com), a biotech firm enabling unprecedented insights into the human immune system, today announced that it has raised USD $11 million (SGD $14.8 million) in a global equity financing round. US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already inte...
Cellics Therapeutics | September 13, 2022
Cellics Therapeutics, Inc., a biotechnology company pioneering Cellular Nanoparticle platform technology for drug development and delivery, announced today that the company has appointed Paul Daruwala as the company's president and chief executive officer, effective on October 1st, 2022. With 30 years of experience in biotech drug development, Daruwala brings a depth of vision, as well as start-up and operational experience to Cellics.
"With our Cellular Nanoparticle plat...
Be Bio | May 20, 2022
Be Biopharma, Inc. (“Be Bio”) and National Resilience, Inc. (Resilience) today announced a strategic collaboration to advance initial programs in Be Bio’s rare disease pipeline. Be Bio’s proprietary engineered B Cell Medicines (BeCM) platform is harnessing the power of the human B cell to create a new class of autologous and allogeneic cellular medicines that durably and redosably produce therapeutic proteins in vivo without toxic pre-conditioning.
The two ...
Verona Pharma | November 19, 2020
A British clinical-stage biotech firm with U.S. base camp in Raleigh is investigating the alternative of repurposing its leading drug candidate to treat COVID-19 patients.
Flush with $200 million after a July raise, the London-based Verona Pharma is now making large walks with its "first-in-class" drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD).
Now, against the backdrop of a pandemic, it’s pushing ahead with a pilot clinic...
Cell and Gene Therapy, Medical
Cell and Gene Therapy, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE